Biotech | April 25, 2022
CanSinoBIO rebrands to reflect commitment to life sciences research
This is the first major brand refresh of CanSinoBIO since its inception in 2009
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
Clobetasol Propionate Foam, 0.05% has an estimated market size of US $ IO million for twelve months ending Dec 2021 according to IQVIA
It is a multi-speciality healthcare brand which delivers a hassle-free experience for all types of cosmetic procedures and elective surgeries with personalized care
Partnership with Modality, award-winning GP super partnership
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
Subscribe To Our Newsletter & Stay Updated
